OBJECTIVE: To estimate prevalence of low bone mineral density (BMD) in perinatally HIV-infected (HIV+) and HIV-exposed but uninfected (HEU) children, and to determine predictors of BMD in HIV+. DESIGN: Cross-sectional analysis within a 15-site United States and Puerto Rico cohort study. METHODS: Total body and lumbar spine BMD were measured using dual energy-X-ray absorptiometry. BMD Z-scores accounted for bone age and sex. Multiple linear regression was used to evaluate differences in Z-scores by HIV status and for predictors of BMD in HIV+. RESULTS: 350 HIV+ and 160 HEU were enrolled. Mean age was 12.6 and 10.7 years for HIV+ and HEU, respectively. Most (87%) HIV+ were receiving HAART. More HIV+ than HEU had total body and lumbar spine Z-scores less than -2.0 (total body: 7 vs. 1%, P = 0.008; lumbar spine: 4 vs. 1%, P = 0.08). Average differences in Z-scores between HIV+ and HEU were attenuated after height and/or weight adjustment. Among HIV+, total body Z-scores were lower in those with higher CD4% and in those who ever used boosted protease inhibitors or lamivudine. Lumbar spine Z-scores were lower with higher peak viral load and CD4%, more years on HAART, and ever use of indinavir. CONCLUSION: Rates of low BMD in HIV+ children were greater than expected based on normal population distributions. These differences were partially explained by delays in growth. As most HIV+ children in this study had not entered their pubertal growth spurt, prepubertal factors associated with BMD, magnified or carried forward, may result in sub-optimal peak BMD in adulthood.
OBJECTIVE: To estimate prevalence of low bone mineral density (BMD) in perinatally HIV-infected (HIV+) and HIV-exposed but uninfected (HEU) children, and to determine predictors of BMD in HIV+. DESIGN: Cross-sectional analysis within a 15-site United States and Puerto Rico cohort study. METHODS: Total body and lumbar spine BMD were measured using dual energy-X-ray absorptiometry. BMD Z-scores accounted for bone age and sex. Multiple linear regression was used to evaluate differences in Z-scores by HIV status and for predictors of BMD in HIV+. RESULTS: 350 HIV+ and 160 HEU were enrolled. Mean age was 12.6 and 10.7 years for HIV+ and HEU, respectively. Most (87%) HIV+ were receiving HAART. More HIV+ than HEU had total body and lumbar spine Z-scores less than -2.0 (total body: 7 vs. 1%, P = 0.008; lumbar spine: 4 vs. 1%, P = 0.08). Average differences in Z-scores between HIV+ and HEU were attenuated after height and/or weight adjustment. Among HIV+, total body Z-scores were lower in those with higher CD4% and in those who ever used boosted protease inhibitors or lamivudine. Lumbar spine Z-scores were lower with higher peak viral load and CD4%, more years on HAART, and ever use of indinavir. CONCLUSION: Rates of low BMD in HIV+ children were greater than expected based on normal population distributions. These differences were partially explained by delays in growth. As most HIV+ children in this study had not entered their pubertal growth spurt, prepubertal factors associated with BMD, magnified or carried forward, may result in sub-optimal peak BMD in adulthood.
Authors: Grace A McComsey; Pablo Tebas; Elizabeth Shane; Michael T Yin; E Turner Overton; Jeannie S Huang; Grace M Aldrovandi; Sandra W Cardoso; Jorge L Santana; Todd T Brown Journal: Clin Infect Dis Date: 2010-10-15 Impact factor: 9.079
Authors: Frank Rauch; Horacio Plotkin; Linda DiMeglio; Raoul H Engelbert; Richard C Henderson; Craig Munns; Deborah Wenkert; Philip Zeitler Journal: J Clin Densitom Date: 2008 Jan-Mar Impact factor: 2.617
Authors: Davide Gibellini; Elisa De Crignis; Cristina Ponti; Laura Cimatti; Marco Borderi; Matilde Tschon; Roberto Giardino; Maria Carla Re Journal: J Med Virol Date: 2008-09 Impact factor: 2.327
Authors: Gayatri Mirani; Paige L Williams; Miriam Chernoff; Mark J Abzug; Myron J Levin; George R Seage; James M Oleske; Murli U Purswani; Rohan Hazra; Shirley Traite; Bonnie Zimmer; Russell B Van Dyke Journal: Clin Infect Dis Date: 2015-08-12 Impact factor: 9.079
Authors: George K Siberry; Denise L Jacobson; Heidi J Kalkwarf; Julia W Wu; Linda A DiMeglio; Ram Yogev; Katherine M Knapp; Justin J Wheeler; Laurie Butler; Rohan Hazra; Tracie L Miller; George R Seage; Russell B Van Dyke; Emily Barr; Mariam Davtyan; Lynne M Mofenson; Kenneth C Rich Journal: Clin Infect Dis Date: 2015-06-09 Impact factor: 9.079
Authors: Julie J Kim-Chang; Lorena Wilson; Cliburn Chan; Bernard Fischer; Guglielmo Venturi; Maureen M Goodenow; Grace Aldrovandi; Thomas J Weber; John W Sleasman Journal: AIDS Res Hum Retroviruses Date: 2019-06-27 Impact factor: 2.205
Authors: Stephen M Arpadi; Cara B Thurman; Faeezah Patel; Jonathan J Kaufman; Renate Strehlau; Megan Burke; Stephanie Shiau; Ashraf Coovadia; Michael T Yin Journal: J Pediatr Date: 2019-08-29 Impact factor: 4.406
Authors: Aylin B Unsal; Aviva S Mattingly; Sara E Jones; Julia B Purdy; James C Reynolds; Jeffrey B Kopp; Rohan Hazra; Colleen M Hadigan Journal: J Clin Endocrinol Metab Date: 2017-08-01 Impact factor: 5.958
Authors: Allison Ross Eckard; Mary Ann OʼRiordan; Julia C Rosebush; Joshua H Ruff; Ann Chahroudi; Danielle Labbato; Julie E Daniels; Monika Uribe-Leitz; Vin Tangpricha; Grace A McComsey Journal: J Acquir Immune Defic Syndr Date: 2017-12-15 Impact factor: 3.731
Authors: Allison Ross Eckard; Julia C Rosebush; S Thera Lee; Mary Ann O'Riordan; Jakob G Habib; Julie E Daniels; Danielle Labbato; Monika Uribe-Leitz; Ann Chahroudi; Grace A McComsey Journal: Pediatr Infect Dis J Date: 2016-12 Impact factor: 2.129